How do you administer this medicine?
What are the possible side effects of Atropine (Redotex NF)?
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Incidence not known
- Blurred vision
- change in color vision
- difficulty seeing at night
- eye pain or stinging
- fast, pounding, or irregular heartbeat or pulse
- increased sensitivity of the eyes to sunlight
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
- Confusion as to time, place, or person
- decreased tearing of the eyes
- dry skin, mouth, or throat
- feeling of warmth
- holding false beliefs that cannot be changed by fact
- redness of the clear part of the eye
- redness of the face, neck, arms, and occasionally, upper chest
- unusual excitement, nervousness, or restlessness
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Copyright 2017 Truven Health Analytics, Inc. All Rights Reserved.
Side effects of Atropine (Redotex NF) in details
Mild to moderate pain may be experienced at the site of injection.
The major and most common side effects of Atropine (Redotex NF) can be attributed to its antimuscarinic action. These include dryness of the mouth, blurred vision, photophobia, confusion, headache, dizziness, tachycardia, palpitations, flushing, urinary hesitance or retention, constipation, abdominal distention, nausea, vomiting, loss of libido and impotency. Anhidrosis may produce heat intolerance and impairment of temperature regulation especially in a hot environment. Larger or toxic doses may produce such central effects as restlessness, tremor, fatigue, locomotor difficulties, delirium, followed by hallucinations, depression and ultimately, medullary paralysis and death. Large doses can also lead to circulatory collapse. In such cases, blood pressure declines and death due to respiratory failure may ensue following paralysis and coma. Hypersensitivity reactions will occasionally occur with Atropine (Redotex NF): these are usually seen as skin rashes, on occasion progressing to exfoliation. Adverse events seen in pediatrics are similar to those that occur in adult patients although central nervous system complaints are often seen earlier and at lower doses.
When Atropine (Redotex NF) and pralidoxime are used together, the signs of atropinization may occur earlier than might be expected than when Atropine (Redotex NF) is used alone. This is especially true if the total dose of Atropine (Redotex NF) has been large and the administration of pralidoxime has been delayed. Excitement and manic behavior immediately following recovery of consciousness have been reported in several cases. However, similar behavior has occurred in cases of organophosphate poisoning that were not treated with pralidoxime.
Amitai et el (JAMA 1990) evaluated the safety of Atropine (Redotex NF)® (Atropine (Redotex NF)) 0.5 mg, 1 mg and 2 mg in a case series of 240 children who received Atropine (Redotex NF)® (Atropine (Redotex NF)) inappropriately (i.e., no nerve agent exposure) during the 1990 Gulf War Period. Overall, severity of atropinization followed a nonlinear correlation with dose. Estimated doses up to 0.045 mg/kg produced no signs of atropinization. Estimated doses between 0.045 mg/kg to 0.175 mg/kg and even greater than 0.175 mg/kg were associated with mild and severe effects respectively. Actual dosage received by children may have been considerably lower than estimated since incomplete injection in many cases was suspected. Regardless, adverse events reported were generally mild and self-limited. Few children required hospitalization. Adverse reactions reported were dilated pupils (43%), tachycardia (39%), dry membranes (35%), flushed skin (20%), temperature 37.8° C or 100° F (4%) and neurologic abnormalities (5%). There was also local pain and swelling. In 91 children with ECGs, no abnormalities were noted other than sinus tachycardia; 22 children had severe tachycardia of 160-190 bpm. Neurologic abnormalities consisted of irritability, agitation, confusion, lethargy, and ataxia.
The following adverse reactions were reported in published literature for Atropine (Redotex NF) in both adults and children:
Cardiovascular: Sinus tachycardia, supraventricular tachycardia, junctional tachycardia, ventricular tachycardia, bradycardia, palpitations, ventricular arrhythmia, ventricular flutter, ventricular fibrillation, atrial arrhythmia, atrial fibrillation, atrial ectopic beats, ventricular premature contractions, bigeminal beats, trigeminal beats, nodal extrasystole, ventricular extrasystole, supraventricular extrasystole, asystole, cardiac syncope, prolongation of sinus node recovery time, cardiac dilation, left ventricular failure, myocardial infarction, intermittent nodal rhythm (no P wave), prolonged P wave, shortened PR segment, R on T phenomenon, shortened RT duration, widening and flattening of QRS complex, prolonged QT interval, flattening of T wave, repolarization abnormalities, altered ST-T waves, retrograde conduction, transient AV dissociation, increased blood pressure, decreased blood pressure, labile blood pressure, weak or impalpable peripheral pulses.
Eye: Mydriasis, blurred vision, pupils poorly reactive to light, photophobia, decreased contrast sensitivity, decreased visual acuity, decreased accommodation, cycloplegia, strabismus, heterophoria, cyclophoria, acute angle closure glaucoma, conjunctivitis, keratoconjunctivitis sicca, blindness, tearing, dry eyes/dry conjunctiva, irritated eyes, crusting of eyelid, blepharitis.
Gastrointestinal: Nausea, abdominal pain, paralytic ileus, decreased bowel sounds, distended abdomen, vomiting, delayed gastric emptying, decreased food absorption, dysphagia.
General:Hyperpyrexia, lethargy, somnolence, chest pain, excessive thirst, weakness, syncope, insomnia, tongue chewing, dehydration, feeling hot, injection site reaction.
Immunologic: Anaphylactic reaction.
Special Investigations: Leukocytosis, hyponatremia, elevated BUN, elevated hemoglobin, elevated erythrocytes, low hemoglobin, hypoglycemia, hyperglycemia, hypokalemia, increase in photic stimulation on EEG, signs of drowsiness on EEG, runs of alpha waves on EEG, alpha waves (EEG) blocked upon opening eyes.
Metabolic: Failure to feed.
Central Nervous System: Ataxia, hallucinations (visual or aural), seizures (generally tonic clonic), abnormal movements, coma, confusion, stupor, dizziness, amnesia, headache, diminished tendon reflexes, hyperreflexia, muscle twitching, opisthotnos, Babinski's reflex/Chaddock's reflex, hypertonia, dysmetria, muscle clonus, sensation of intoxication, difficulty concentrating, vertigo, dysarthria.
Psychiatric: Agitation, restlessness, delirium, paranoia, anxiety, mental disorders, mania, withdrawn behavior, behavior changes.
Genitourinary: Difficulty in micturation, urine urgency distended urinary bladder, urine retention, bed-wetting.
Pulmonary: Tachypnea, slow respirations, shallow respirations, breathing difficulty, labored respirations, inspiratory stridor, laryngitis, laryngospasm, pulmonary edema, respiratory failure, subcostal recession.
Dermatologic: Dry mucous membranes, dry warm skin, flushed skin, oral lesions, dermatitis, petechiae rash, macular rash papular rash, maculopapular rash, scarlatiniform rash, erythematous rash, sweating/moist skin, cold skin, cyanosed skin, salivation.
Drug Abuse And Dependence
Atropine (Redotex NF) possesses no known potential for dependence.
What is the most important information I should know about Atropine (Redotex NF)?
- If your symptoms do not get better within a few days or if they get worse, check with your doctor.
- Atropine (Redotex NF) may cause drowsiness or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Atropine (Redotex NF) with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.
- Do not drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Atropine (Redotex NF); it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.
- Do not become overheated in hot weather or while you are being active; heatstroke may occur.
- Report any symptoms of fluid or electrolyte loss to your doctor: dry mouth; thirst; weakness; lethargy; drowsiness; restlessness; muscle pain or cramps; muscle weakness; low blood pressure; infrequent urination; rapid heartbeat; stomach disorders such as nausea and vomiting.
- Atropine (Redotex NF) may make your eyes more sensitive to sunlight. It may help to wear sunglasses.
- Tell your doctor or dentist that you take Atropine (Redotex NF) before you receive any medical or dental care, emergency care, or surgery.
- Use Atropine (Redotex NF) with caution in the ELDERLY; they may be more sensitive to its effects.
- Atropine (Redotex NF) should be used with extreme caution in CHILDREN younger than 13 years old; safety and effectiveness in these children have not been confirmed.
- PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Atropine (Redotex NF) while you are pregnant. It is not known if Atropine (Redotex NF) is found in breast milk. If you are or will be breast-feeding while you use Atropine (Redotex NF), check with your doctor. Discuss any possible risks to your baby.
Atropine (Redotex NF) contraindications
Known hypersensitivity to Atropine (Redotex NF) or other anticholinergic agents.
Severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; gastrointestinal obstruction eg, pyloroduodenal stenosis, achalasia, cardiospasm, paralytic ileus, intestinal atony; closed-angle glaucoma; obstructive uropathy eg, bladder neck obstruction caused by prostatic hypertrophy; myasthenia gravis; tachycardia secondary to cardiac insufficiency or thyrotoxicosis; acute hemorrhage with unstable cardiovascular status; febrile patients or patients exposed to elevated ambient temperature due to risk of provoking hyperpyrexia and heat prostration; prostatic enlargement; pregnancy-induced hypertension.
Side effects of Cathine (Redotex NF) in details
In large doses giddiness, headache, nausea, vomiting, sweating, dryness of the mouth and thirst, tachycardia, precordial pain, palpitation, difficulty in micturition, muscular weakness and tremors, anxiety, restlessness and insomnia may occur.
Some patients may exhibit these symptoms with the therapeutic dose. These agents may produce psychotic reactions, agitation and excitability. They should be used with caution in patients with history of psychiatric illness. Prolonged administration has no cumulative effect but tolerance with dependence has been reported.
Use with caution in patients receiving chloroform, cyclopropane, halothane or other halogenated anaesthetics.
this medicine may diminish the effects of guanethidine and may increase the possibility of arrythmias in digitalised patients. this medicine should be taken with caution by patients with organic heart disease, cardiac decompensation or angina of effort in patients receiving digitalis.
The effects of this medicine may be diminished or enhanced by tricyclic anti-depressants.
In patients with prostatic enlargement, it may increase difficulty with micturition.
The preparation should not be taken late in the afternoon because of its stimulant effect on the central nervous system.
These agents are liable to be abused. They should be used with extreme caution in patients with a history of drug or alcohol abuse and in patients with personality disorders. There is a lack of evidence for efficacy in the long-term management of obesity.
Systolic and diastolic blood pressure may be increased, especially with high doses and anginal pain or cardiac arrhythmia’s may occur.
These agents should be administered cautiously to patients suffering from cardiovascular disease (especially coronary insufficiency), hypertension, thyrotoxicosis and narrow angle glaucoma.
Cathine (Redotex NF) contraindications
Patients treated with MAOI or stopped MAOI within the last 2 wk; moderate or severe hypertension; pulmonary hypertension; structural cardiac abnormalities or advanced arteriosclerosis; adrenal tumour; hyperthyroidism or hyperexcitability; coronary thrombosis; closed-angle glaucoma; pregnancy.
- DailyMed. "ATROPINE SULFATE; EDROPHONIUM CHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "Atropine: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "(1S,2R)-(+)-Norephedrine: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Redotex NF are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Redotex NF. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported side effectsNo survey data has been collected yet
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology